Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company

Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024

LITTLETON, Colo., Oct. 05, 2023 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders, today announced it has entered into an exclusive distribution agreement with NOUM DMCC (“Noum”), a Dubai-based company focused on diagnostic testing and treatment product distribution for healthcare providers and hospital networks treating obstructive sleep apnea patients throughout the Middle East-North Africa (MENA) region.

Since 2020, Noum has been the exclusive distributor for SleepImage home sleep tests in the MENA region, complementing Vivos activities as a distributor of SleepImage diagnostic products in the United States and Canada. Noum has developed and maintains key strategic relationships and accounts for diagnostic testing with sleep physicians, sleep centers, hospitals and other healthcare providers across the MENA region.

This agreement allows Noum to meet the rapidly growing demand from their customers for effective treatment options that are alternatives to CPAP. Under the terms of the agreement, Noum has been given exclusive distribution rights for Vivos products and services in Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Jordan, Lebanon and Palestine. Noum will immediately seek regulatory approvals in the various countries for Vivos medical devices. Noum expects approval times to vary from a few weeks to several months, depending on the country, but has already scheduled an initial provider training event on Vivos oral appliances and technology for early 2024 in Dubai. The parties expected that Vivos products will eventually be manufactured locally in the region under a future license agreement currently being finalized between Vivos and Noum.

Nader Sughair, Chief Executive Officer of Noum, shared his views on the potential for Vivos products in the Middle East, “The demand for clinical alternatives to CPAP in the MENA region has taken off over the past year. As more people are being tested for breathing and sleep disorders, a greater number are testing positive, and many cannot or will not tolerate CPAP therapy. We already have over 40 dentists from our region who are anxious to be trained and get started with Vivos, and we are looking forward to a long and mutually beneficial relationship.”